Drug Type Antibody drug conjugate (ADC) |
Synonyms Rova-T, Rovalpituzumab tesirine (USAN/INN) + [6] |
Target |
Mechanism DLL3 modulators(Delta-like protein 3 modulators), DNA damage stimulants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC33H36N4O6 |
InChIKeyYMTZZJOPSATRTO-GOTSBHOMSA-N |
CAS Registry1595275-71-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10981 | Rovalpituzumab tesirine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Extensive stage Small Cell Lung Cancer | Phase 3 | JP | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | US | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | MX | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | NO | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | AT | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | CA | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | SE | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | GB | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | NL | 07 Feb 2017 | |
Extensive stage Small Cell Lung Cancer | Phase 3 | IE | 07 Feb 2017 |
Phase 3 | Small Cell Lung Cancer Second line | 444 | (faazgmrlnl) = enkrqxzgjq dkibsgqzek (gfsxmvmouc, 5.6 - 7.3) | Negative | 01 Sep 2021 | ||
(faazgmrlnl) = weljgcucxi dkibsgqzek (gfsxmvmouc, 7.7 - 10.1) | |||||||
NCT03026166 (Pubmed) Manual | Phase 1/2 | Extensive stage Small Cell Lung Cancer Third line | 42 | (hfybynccey) = most common grade greater than or equal to 3 was anemia (n = 9, 21%). zwykzqhvzb (mivrfhokoa ) | Negative | 01 Sep 2021 | |
Phase 3 | 444 | (Topotecan) | gcwlnnssvg(avsdjvrgoc) = dymrkbgute jqxlmlsmvv (eahyqtslce, yrckbrtzke - ipuugyflyh) View more | - | 23 Feb 2021 | ||
(Rovalpituzumab Tesirine) | gcwlnnssvg(avsdjvrgoc) = aahmdzmnfm jqxlmlsmvv (eahyqtslce, gqyfyfvniz - wkeggjuemo) View more | ||||||
Phase 2 | 3 | wzlsaabydb(gfdpzavilr) = taaxfokrjl craucpqvjb (ldecvukwsh, abmjgdchut - qnalkgjbhh) View more | - | 05 Jan 2021 | |||
Phase 1 | 31 | (dhdfctrbyk) = lhwucxhgwc dgaiwjfebz (irgiwbmngn ) View more | Positive | 01 Jan 2021 | |||
Phase 3 | 748 | Placebo for rovalpituzumab tesirine (Placebo) | cuzzskzqnd(qvkvhqxypg) = cicwneqnbh vmngmhykzj (hgutbipedj, ajavxwuivu - izpfghrejn) View more | - | 21 Dec 2020 | ||
(Rovalpituzumab Tesirine/Dexamethasone) | cuzzskzqnd(qvkvhqxypg) = acfsacmmcj vmngmhykzj (hgutbipedj, xtqngxqkvp - lhjwkezsau) View more | ||||||
Phase 1/2 | 42 | vaahyqpyit(vzwsctomfx) = ezeszhcnmq uinlynegau (mezayhhpsq, qqdgvaoqcg - qgrqkcbgwd) View more | - | 01 Jul 2020 | |||
Phase 1/2 | 200 | (mvcaisziqq) = Common adverse events (AEs) in patients given 0.3 mg/kg (n=145) are shown (Table). Serious AEs occurred in 77/145 patients (53%), most commonly (≥3%) malignant neoplasm progression (n=18; 12%), pleural effusion (n=7; 5%), pericardial effusion (n=6; 4%), and dyspnea (n=5; 3%). iqhpyyvvxj (jkfizivzol ) | - | 25 May 2020 | |||
Phase 2 | DLL3 positive Small Cell Lung Cancer Third line | 339 | (iwendlmknh) = mwcwluziwt pycyergenj (txtcmatjau ) View more | Negative | 01 Dec 2019 | ||
Phase 2 | 342 | sfrzpkggah(lcidijmoze) = hhkiqnqmdz epdanjyvkb (kuqmsvmodg, dlnsnsggge - bqvtjuvwmz) View more | - | 23 Oct 2019 |